Oral Semaglutide in the Management of Type 2 Diabetes: A Report on the Evidence to Date

Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy - New Zealand
doi 10.2147/dmso.s229802
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Informa UK Limited

Related search

54-Or: Oral Semaglutide vs. Empagliflozin Added on to Metformin Monotherapy in Uncontrolled Type 2 Diabetes: PIONEER 2

Diabetes
Internal MedicineEndocrinologyMetabolismDiabetes
2019English

Semaglutide: A New GLP‐1 Analogue for Type 2 Diabetes

Prescriber
Pharmacology
2019English

Clinical Potential of Treatment With Semaglutide in Type 2 Diabetes Patients

Drugs in Context
Molecular MedicinePharmacology
2019English

Exercise for the Management of Type 2 Diabetes: A Review of the Evidence

Acta Diabetologica
Internal MedicineMedicineDiabetesMetabolismEndocrinology
2009English

1004-P: Oral Semaglutide vs. Placebo in Patients With Type 2 Diabetes and Moderate Renal Impairment: PIONEER 5

Diabetes
Internal MedicineEndocrinologyMetabolismDiabetes
2019English

Management of Psoriasis in Pregnancy – A Review of the Evidence to Date

Drugs in Context
Molecular MedicinePharmacology
2020English

The Oral Microflora in Obesity and Type-2 Diabetes

Journal of Oral Microbiology
Infectious DiseasesMicrobiologyDentistry
2012English

Cryoablation in the Management of Breast Cancer: Evidence to Date

Breast Cancer: Targets and Therapy
Oncology
2019English

Counterpoint: Evidence-Based Prevention of Type 2 Diabetes: The Power of Lifestyle Management

Diabetes Care
Internal MedicineEndocrinologyAdvancedMetabolismSpecialized NursingDiabetes
2007English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy